Retatrutide is an investigational Eli Lilly triple agonist. It targets GLP-1, GIP and glucagon, and remains in clinical trial stages, not yet commercially available. In the trial record, the reported adverse events are gastrointestinal plus skin sensation effects. In TRIUMPH-4, nausea, diarrhea, constipation, vomiting and decreased appetite occurred more often with retatrutide than placebo, and dysesthesia was reported in 8.8 percent at 9 mg and 20.9 percent at 12 mg versus 0.7 percent on placebo.

In the Phase 2 trial, transient mostly mild-to-moderate gastrointestinal events were the most frequently reported adverse events. No anhedonia, emotional blunting, relationship, or cortisol finding appears in the trial reporting I retrieved.

The "falling out of love" idea is traceable to social media, not to a study. CP24 reports that an Instagram user said there is a "theory" that retatrutide, also called "reta," will make you "fall out of love" because it affects dopamine and reward pathways, and that another user described the "dark side of retatrutide" as anhedonia.

A physician and nutrition expert, Dr. Mary Sco, told CTV News that this social media chatter is "theoretical" so far, since no evidence has been presented of retatrutide having any effect on users' emotions regarding love or relationships. A commentator tracking the coverage noted that a Guardian story explored viral claims that experimental drugs like retatrutide are making people "fall out of love," while Telegraph-amplified reporting suggested a "divorce boom," and called this a familiar exercise in hyperbole , adding that the Guardian piece leans heavily on anecdotes, TikTok videos and personal reports of emotional flatness or reduced desire .

There is a real, separate, and weaker-than-claimed signal about reward blunting on GLP-1 drugs generally. Coverage of Washington Post reporting describes users of semaglutide-based drugs reporting "Ozempic personality," a reduced ability to feel pleasure or emotional connection, which doctors say aligns with anhedonia, diminished enjoyment of activities including socializing, exercise, music, food and romantic relationships. But the status of that signal is explicitly unsettled: anhedonia is not currently a formally established or quantified side effect of GLP-1 treatment, and reports of emotional blunting come largely from individual patient experiences, post-marketing observations and emerging research. One clinician quoted in consumer press said the phenomenon is "unexplored and anecdotal in the context of GLP-1 drugs" .

The dopamine-blunting mechanism, as stated by an expert in the same CP24 piece, is described as theoretical and food-directed. Sco said that in theory all weight-loss medications prescribed for obesity and type 2 diabetes can "blunt" the amount of dopamine released when eating food, and that the drive to eat is fueled by the brain rewarding a survival-enhancing activity.

Population-level psychiatric evidence for the class does not point in the direction the claim assumes, and it conflicts. The Swedish national cohort study found a 42 percent lower risk of worsening mental illness among semaglutide users and an 18 percent decreased risk with liraglutide, but not with exenatide or dulaglutide , and the same paper states that the consensus appears to be that GLP-1 receptor agonists are not usually associated with adverse psychiatric outcomes once confounding is controlled for . Pointing the other way, a systematic review cites a large study in which GLP-1 receptor agonist users showed a 108 percent increased risk of anxiety disorders, a 195 percent higher risk of major depressive disorder and a 106 percent increased risk of suicidal behaviour , while also noting that other studies suggest the contrary .

On the gambling anecdote, there is a genuine research direction but the trial evidence is thin. A review of GLP-1 agonists and alcohol use disorder notes anecdotal reports of reduced craving for alcohol and other addictive substances, and states that the one published GLP-1 trial for alcohol use to date resulted in null findings overall, with significant reductions only in a subgroup of participants with obesity.

On what people are actually injecting: products sold online as "retatrutide peptide" are unregulated listings marketed as research chemicals, not the same as the clinically trialed medication, and their contents cannot be verified.

Lilly told Medscape that the FDA has made clear that sales of unapproved retatrutide to consumers are illegal and that black-market sellers are selling illegal drugs.